全球医疗保健公司OSR Holdings签署收购Woori IO的条款协议，Woori IO是非侵入性血糖监测技术的先驱公司-动脉网

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

CISION 等信源发布 2025-07-24 19:30



可切换为仅中文







BELLEVUE, Wash.

贝尔维尤，华盛顿州

and SEOUL, South Korea

韩国首尔

，

July 24, 2025

2025年7月24日

/PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:

/PRNewswire/ -- OSR控股有限公司（纳斯达克：

OSRH

开放性高速铁路枢纽

), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ('Term Sheet') with Woori IO Co., Ltd. ('WORIO'), a South Korean medical device company developing next-generation noninvasive glucose monitoring technology. The agreement sets forth certain key terms for a strategic acquisition of WORIO by OSR Holdings' Korean affiliate, OSR Holdings Co., Ltd.

），一家推动生物医学和健康创新的全球医疗保健公司，今天宣布已与韩国医疗设备公司 Woori IO Co., Ltd.（“WORIO”）签署了一份条款清单（“条款清单”）。该公司正在开发下一代无创血糖监测技术。该协议规定了OSR Holdings的韩国子公司OSR Holdings Co., Ltd.对WORIO进行战略性收购的某些关键条款。

('OSRK')..

Under the proposed structure, WORIO will become a wholly owned subsidiary of OSRK. Shareholders of WORIO will receive newly issued shares of OSRK through the share exchange and may be eligible to convert them into OSRH common stock traded on NASDAQ, subject to certain conditions including '

根据拟议的结构，WORIO将成为OSRK的全资子公司。WORIO的股东将通过股份交换获得新发行的OSRK股份，并可能符合将其转换为在纳斯达克交易的OSRH普通股的条件，但需满足某些条件，包括 '

$10

10美元

per OSRH share' condition.

每个OSRH股份的条件。

Specifically, WORIO shareholders may convert their OSRK shares into OSRH shares at a fixed exchange ratio of 1 OSRK share = 12.96 OSRH shares, provided that OSRH's stock price reaches

具体而言，WORIO 的股东可以按照 1 股 OSRK = 12.96 股 OSRH 的固定兑换比率，将他们的 OSRK 股份转换为 OSRH 股份，但前提是 OSRH 的股价达到

$10.00

10.00美元

at least once within three years following the signing of the Term Sheet. If this condition is not met, the parties have agreed to renegotiate in good faith. The agreement includes a 6-month exclusivity period, during which OSRK will conduct confirmatory legal and financial due diligence with a target to complete this transaction within this exclusivity period..

在签署《条款清单》后的三年内至少一次。如果此条件未满足，双方同意善意重新谈判。协议包括一个6个月的排他期，在此期间，OSRK将进行确认性的法律和财务尽职调查，目标是在这个排他期内完成此项交易。

WORIO's proprietary platform uses near-infrared spectroscopy (NIRS) to measure glucose without needles, sensors, or skin penetration — representing a truly noninvasive alternative to today's continuous glucose monitors (CGMs). Its solution aims to eliminate the burden of pain and daily finger pricks for millions of people with diabetes. According to recent global market research, the blood glucose monitoring devices market is expected to exceed .

WORIO的专有平台使用近红外光谱（NIRS）技术，在无需针头、传感器或皮肤穿透的情况下测量葡萄糖水平——这代表了当今连续血糖监测仪（CGM）的一种真正无创的替代方案。其解决方案旨在消除数百万糖尿病患者每日面临的疼痛和手指穿刺的负担。根据最近的全球市场研究，血糖监测设备市场预计将会超过。

$40 billion

400亿美元

by 2030, growing at a CAGR of 8–10%, driven by rising diabetes prevalence and the convergence of medical technology with consumer electronics. Demand for noninvasive and wearable monitoring systems is expected to be a major growth driver. Dexcom, one of the market leaders in minimally invasive CGM which is the current standard of care has more than .

到2030年，市场规模预计将以8-10%的复合年增长率增长，这一增长主要受到糖尿病患病率上升以及医疗技术与消费电子融合的推动。对于非侵入式和可穿戴监测系统的需求预计将成为主要的增长动力。Dexcom是当前护理标准——微创连续血糖监测（CGM）领域的市场领导者之一，其影响力巨大。

$32 billion

320亿美元

in market capitalization (as of

在市值方面（截至

July 11

7月11日

), underscoring the significant commercial potential of advanced glucose monitoring solutions. Noninvasive alternatives hold tremendous promise and are poised to become an integral part of diabetes management in the future.

），突显了先进葡萄糖监测解决方案的巨大商业潜力。非侵入性替代方案具有极大的前景，未来有望成为糖尿病管理的重要组成部分。

WORIO has completed a proof-of-concept study with the Korea University Hospital (Guro) to validate the accuracy and effectiveness of its prototype devices and the data measured by them, based on which the company plans to enter a larger confirmatory trial to be registered with the Ministry of Food and Drug Safety (MFDS) of Korea for medical device approval pathway.

WORIO 已与韩国大学医院（九老）完成了一项概念验证研究，以验证其原型设备及其测量数据的准确性和有效性。基于此，该公司计划进入更大规模的确证试验，并向韩国食品药品安全部 (MFDS) 注册，以申请医疗器械审批通道。

WORIO's noninvasive technology is well .

WORIO的非侵入式技术很好。

positioned

定位

to be integrated into wearable glucose monitoring devices such as smart watches — WORIO has been selected by Samsung Electronics' innovative startup program ('C-Lab Outside') in Q1 2025.

将被整合到可穿戴的葡萄糖监测设备中，例如智能手表 —— WORIO 已被三星电子的创新初创公司计划（“C-Lab Outside”）在 2025 年第一季度选中。

'We believe this initial milestone with Woori IO aligns strongly with our mission to accelerate breakthrough healthcare innovations with global impact,' said

“我们相信，与Woori IO达成的这一初步里程碑，与我们加速具有全球影响力的突破性医疗创新的使命高度契合，”

Peter Hwang

彼得·黄

, CEO of OSRH. 'Woori IO's breakthrough noninvasive glucose monitoring platform, coupled with its high-profile partnership with global companies, puts OSRH in a position to become a first mover in this fast-growing global market.'

OSRH公司首席执行官表示：“Woori IO突破性的无创血糖监测平台，加上其与全球知名公司的高调合作，使OSRH有望成为这一快速增长的全球市场的先行者。”

Following the signing of this Term Sheet, both parties will proceed with due diligence and aim to execute definitive agreements within the 6 months exclusivity period.

本条款签署后，双方将进行尽职调查，并力求在6个月的排他期内签订最终协议。

About OSR Holdings, Inc.

关于OSR控股公司

OSR Holdings, Inc. (NASDAQ:

OSR控股有限公司（纳斯达克：

OSRH

操作系统资源处理（OSRH）

) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development.

）是一家全球医疗保健控股公司，致力于推进生物医学创新方法以促进健康和保健，支持全球健康成果。通过其子公司，OSRH涉足免疫肿瘤学、再生生物学和医疗设备分销领域。OSRH的愿景是收购并运营一批创新的医疗保健和健康公司，通过尖端的研发改善患者护理。

For more information, visit .

欲了解更多信息，请访问。

www.OSR-Holdings.com

www.OSR控股公司.com

。

About Woori IO Co., Ltd.

关于Woori IO有限公司。

Woori IO is a medical device company based in Jeonju,

Woori IO 是一家位于全州的医疗器械公司，

South Korea

韩国

, focused on the development of noninvasive biosensing solutions. Its proprietary NIRS-based glucose monitoring system enables accurate, pain-free, and user-friendly diabetes management, with strong potential for wearable integration. For more information, visit

，专注于非侵入式生物传感解决方案的开发。其专有的基于NIRS的葡萄糖监测系统能够实现准确、无痛且用户友好的糖尿病管理，并具有强大的可穿戴设备集成潜力。欲了解更多信息，请访问

www.Woori.io

。

Contact:

联系人：

Investor Relations

投资者关系

OSR Holdings, Inc.

OSR控股有限公司

Email:

电子邮件：

IR@osr-holdings.com